By KPC Mandere Onyinkwa
The Kenya Medical Association (KMA) has announced its support for the introduction of lenacapavir as a new option for HIV pre-exposure prophylaxis (PrEP) in Kenya.
KMA described the injectable drug as a groundbreaking addition to the country’s HIV prevention toolkit.
The endorsement comes after two trials which showed that lenacapavir significantly reduced HIV acquisition compared to oral PrEP.
KMA President Dr. Simon Kigondu emphasized the importance of the new intervention, saying, “KMA is confident that this novel health technology will significantly contribute to ongoing efforts to reduce HIV incidence in Kenya and globally.”
The association highlighted several key considerations for rollout. HIV testing must remain central to PrEP delivery, with rapid diagnostic tests and self-testing recommended before and during treatment.
Lenacapavir should also be integrated into broader combination prevention strategies, including screening for sexually transmitted infections and hepatitis, condom use, and behavioral interventions.
Accessibility was another major theme. KMA stressed that both public and private health facilities should be included in rollout plans to ensure equitable access.
Surveillance systems will be needed to monitor for breakthrough infections and resistance mutations, while healthcare providers must carefully screen for potential drug interactions, particularly with tuberculosis treatments and certain anticonvulsants.
On sustainability, the association warned that Kenya’s HIV response has long relied on donor funding, which may not be sufficient in the future.
“Sustainability must be embedded from the outset to ensure uninterrupted access, program continuity, and long-term impact,” the statement noted.
KMA recommended integrating lenacapavir into national HIV financing frameworks, strengthening domestic resource mobilization, and exploring innovative funding models such as public-private partnerships.
The association concluded by pledging to work closely with the Ministry of Health and other stakeholders to ensure safe, effective, and equitable implementation of lenacapavir as part of Kenya’s HIV prevention strategy.